American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting
ASTRO 2025 Prostate Cancer
- ASTRO 2025: Discussant: Biomarker Breakthroughs in Prostate Cancer
- ASTRO 2025: Influence of HSD3B1 Genotype on Prostate Cancer Outcomes Following Definitive Radiation Therapy with ADT: A Retrospective Analysis of the Million Veterans Program
- ASTRO 2025: Predictive Role of Tumor Fraction and Copy Number Alteration Burden in mCRPC Patients Receiving Tandem Actinium-Lutetium Radionuclide Therapy
- ASTRO 2025: Validation of Six Androgen Production, Uptake and Conversion Genes in the ECOG-ACRIN E3805 CHAARTED Prostate Cancer Trial
- ASTRO 2025: Genomic Classifier and Multimodal AI Biomarker in Localized Prostate Cancer: Two Sides of the Same Coin
ASTRO 2025 Bladder Cancer
- ASTRO 2025: Trials in Progress: CONSOLIDATE – Concurrent Radiotherapy with Enfortumab vedotin for Locally Advanced Bladder Cancer
- ASTRO 2025: Bladder Only vs. Whole Pelvis Radiotherapy in Trimodality Treatment for Lymph Node Negative Urothelial Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
- ASTRO 2025: Bladder Adjuvant Radiotherapy (BART): Clinical Outcomes from a Phase III Multicenter Randomized Controlled Trial
- ASTRO 2025: Bladder-specific 15-Gene Transcriptomic Signature Predicts (Chemo)radiation Therapy Response in Muscle-Invasive Bladder Cancer
- ASTRO 2025: Early Detection of Metastatic Progression by Circulating Tumor DNA in Patients Undergoing Bladder-Preserving Trimodality Therapy
ASTRO 2025 Kidney Cancer
- ASTRO 2025: Ultra-Hypofractionated Stereotactic Ablative Body Radiotherapy (SABR) for Primary Renal Cell Carcinoma: Pooled Outcomes from the FASTRACK and FASTRACK II Clinical Trials
- ASTRO 2025: 265 - Long-Term Follow-up Results after Stereotactic Body Radiotherapy for Primary Renal Cell Carcinoma: A Prospective Multicenter Phase 2 Trial
- ASTRO 2025: Stereotactic Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer: Final Results of a Phase IIb Trial
- ASTRO 2025: Discussant: Revelations in Renal Radiotherapy
- ASTRO 2025: Neoadjuvant Pembrolizumab and Stereotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma (NAPSTER): A Phase II Randomized Clinical Trial